TY - JOUR
T1 - Sarcopenia and Chronic Complications of Type 2 Diabetes Mellitus
AU - Purnamasari, Dyah
AU - Tetrasiwi, Erpryta Nurdia
AU - Kartiko, Gracia Jovita
AU - Astrella, Cindy
AU - Husam, Khoirul
AU - Laksmi, Purwita Wijaya
N1 - Funding Information:
to thank Christian Tricaesario for writing and editing assistance, Nissha Audina Fitri for language assistance, and Universitas Indonesia for funding this research through PUTI Grant with contract number NKB-3925/UN2.RST/HKP.05.00/2020.
Funding Information:
Funding: This work was supported by PUTI Grant
Publisher Copyright:
© by Lab & Life Press.
PY - 2022
Y1 - 2022
N2 - Sarcopenia, defined as the loss of skeletal muscle mass and strength and/or a decrease in physical performance, is classically related to aging. However, chronic disease, including type 2 diabetes mellitus (T2DM), may accelerate the development of sarcopenia. Previous studies found strong association between T2DM and sarcopenia. Insulin resistance that exists in T2DM is thought to be the key mediator for impaired physical function and mobility which may lead to sarcopenia. T2DM may cause sarcopenia through the mediation of insulin resistance, inflammation, accumulation of advanced glycation end-products, and oxidative stress that may affect muscle mass and strength, protein metabolism, and vascular and mitochondrial dysfunction. On the other hand, loss of muscle in sarcopenia may play a role in the development of T2DM through the decreased production of myokines that play a role in glucose and fat metabolism. This review highlights the findings of existing literature on the relationship between T2DM and sarcopenia which emphasize the pathophysiology, chronic vascular complications, and the course of macrovascular and microvascular complications in T2DM..
AB - Sarcopenia, defined as the loss of skeletal muscle mass and strength and/or a decrease in physical performance, is classically related to aging. However, chronic disease, including type 2 diabetes mellitus (T2DM), may accelerate the development of sarcopenia. Previous studies found strong association between T2DM and sarcopenia. Insulin resistance that exists in T2DM is thought to be the key mediator for impaired physical function and mobility which may lead to sarcopenia. T2DM may cause sarcopenia through the mediation of insulin resistance, inflammation, accumulation of advanced glycation end-products, and oxidative stress that may affect muscle mass and strength, protein metabolism, and vascular and mitochondrial dysfunction. On the other hand, loss of muscle in sarcopenia may play a role in the development of T2DM through the decreased production of myokines that play a role in glucose and fat metabolism. This review highlights the findings of existing literature on the relationship between T2DM and sarcopenia which emphasize the pathophysiology, chronic vascular complications, and the course of macrovascular and microvascular complications in T2DM..
KW - atherosclerosis
KW - nephropathy
KW - neuropathy
KW - retinopathy
KW - sarcopenia
KW - type 2 diabetes mellitus
UR - http://www.scopus.com/inward/record.url?scp=85138741895&partnerID=8YFLogxK
U2 - 10.1900/RDS.2022.18.157
DO - 10.1900/RDS.2022.18.157
M3 - Review article
AN - SCOPUS:85138741895
VL - 18
SP - 157
EP - 165
JO - Review of Diabetic Studies
JF - Review of Diabetic Studies
SN - 1613-6071
IS - 3
ER -